Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia

Schizophrenia Bulletin

Volumn 42, Issue 1, 2016, Pages 19-33

  Keefe, Richard S E ^a   Haig, George M ^b   Marder, Stephen R ^c   Harvey, Philip D ^d   Dunayevich, Eduardo ^e   Medalia, Alice ^f   Davidson, Michael ^g   Lombardo, Ilise ^h   Bowie, Christopher R ⁱ   Buchanan, Robert W ^j   Bugarski Kirola, Dragana ^k   Carpenter, William T ^j   Csernansky, John T ^l   Dago, Pedro L ^l   Durand, Dante M ^d   Frese, Frederick J ^m   Goff, Donald C ⁿ   Gold, James M ^j   Hooker, Christine I ^o   Kopelowicz, Alex ^p   Loebel, Antony ^q   McGurk, Susan R ^r   Opler, Lewis A ^f   Pinkham, Amy E ^s   Stern, Robert G ^t   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ABBVIE INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e Clinical Protocol Development   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g SHEBA MEDICAL CENTER   (Israel)

^h FORUM Pharmaceuticals   (United States)

ⁱ QUEEN S UNIVERSITY   (Canada)

^j UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^k F HOFFMANN LA ROCHE LTD   (Switzerland)

^l NORTHWESTERN UNIVERSITY   (United States)

^m Northeastern Ohio Medical University   (United States)

ⁿ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o HARVARD UNIVERSITY   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q Global Clinical Development Organon   (United States)

^r BOSTON UNIVERSITY   (United States)

^s UNIVERSITY OF TEXAS AT DALLAS   (United States)

^t Essex County Hospital Center   (United States)

more..

Author keywords

cognitive assessment; neuropsychology; treatment

Indexed keywords

NEUROLEPTIC AGENT; NOOTROPIC AGENT;

COGNITION DISORDERS; CONSENSUS DEVELOPMENT; HUMAN; NEUROPSYCHOLOGICAL TEST; PATIENT SELECTION; PROCEDURES; PSYCHOLOGY; PSYCHOSOCIAL REHABILITATION; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; HUMANS; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PATIENT SELECTION; PSYCHIATRIC REHABILITATION; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 84954348301     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv111     Document Type: Article

References (59)

1. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
2. Harvey PD, Lombardi J, Leibman M, et al. Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: A follow-up study. Schizophr Res. 1996;22:223-231.
3. Keefe RS, Sweeney JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1061-1071.
4. Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009;166:675-682.
5. Marder SR, Fenton W, Youens K. Schizophrenia, IX: cognition in schizophrenia-The MATRICS initiative. Am J Psychiatry. 2004;161:25.
6. The NEWMEDS Project. www.NEWMEDS-europe.com. Accessed February 28, 2014.
7. Keefe RS, Buchanan RW, Marder SR, et al. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull. 2013;39:417-435.
8. Schizophrenia Research Forum Drugs in Trial. Brain and Behavior Research Foundation. http://www.schizophreniaforum. org/res/drc/drug-tables.asp. Accessed November 24, 2014.
9. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A metaanalysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168:472-485.
10. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72:29-39.
11. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157:549-559.
12. Green MF, Schooler NR, Kern RS, et al. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry. 2011;168:400-407.
13. Buchanan RW, Keefe RS, Lieberman JA, et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry. 2011;69:442-449.
14. Umbricht D, Keefe RS, Murray S, et al. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2014;39:1568-1577.
15. Gray BE, McMahon RP, Green MF, et al. Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery. Schizophr Res. 2014; 159:182-187.
16. Heaton RK, Temkin N, Dikmen S, et al. Detecting change: A comparison of three neuropsychological methods, using normal and clinical samples. Arch Clin Neuropsychol. 2001;16:75-91.
17. Goldberg TE, Keefe RS, Goldman RS, Robinson DG, Harvey PD. Circumstances under which practice does not make perfect: A review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology. 2010;35:1053-1062.
18. Harvey PD, Heaton RK, Palmer BA, Mohamed S, Kennedy J, Brickman A. Stability of cognitive impairment in elderly schizophrenic patients receiving conventional antipsychotic treatment. Am J Psychiatry. 2005;162:110-117.
19. Harvey PD, Reichenberg A, Bowie CR, Patterson TL, Heaton RK. The course of neuropsychological performance and functional capacity in older patients with schizophrenia: influences of previous history of long-term institutional stay. Biol Psychiatry. 2010;67:933-939.
20. Leifker FR, Bowie CR, Harvey PD. Determinants of everyday outcomes in schizophrenia: The influences of cognitive impairment, functional capacity, and symptoms. Schizophr Res. 2009;115:82-87.
21. Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo-and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013;23:1373-1382.
22. Velligan DI, DiCocco M, Bow-Thomas CC, et al. A brief cognitive assessment for use with schizophrenia patients in community clinics. Schizophr Res. 2004;71:273-283.
23. Hurford IM, Marder SR, Keefe RS, Reise SP, Bilder RM. A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophr Bull. 2011;37:538-545.
24. Fervaha G, Agid O, Foussias G, Remington G. Toward a more parsimonious assessment of neurocognition in schizophrenia: A 10-minute assessment tool. J Psychiatr Res. 2014;52:50-56.
25. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006;31:2033-2046.
26. Harvey PD, Velligan DI, Bellack AS. Performance-based measures of functional skills: usefulness in clinical treatment studies. Schizophr Bull. 2007;33:1138-1148.
27. Mausbach BT, Depp CA, Bowie CR, et al. Sensitivity and specificity of the UCSD Performance-based Skills Assessment (UPSA-B) for identifying functional milestones in schizophrenia. Schizophr Res. 2011;132:165-170.
28. Mausbach BT, Bowie CR, Harvey PD, et al. Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia. J Psychiatr Res. 2008;42:320-327.
29. Bowie CR, Leung WW, Reichenberg A, et al. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry. 2008;63:505-511.
30. Depp CA, Mausbach BT, Bowie C, et al. Determinants of occupational and residential functioning in bipolar disorder. J Affect Disord. 2012;136:812-818.
31. Gould F, Bowie CR, Harvey PD. The influence of demographic factors on functional capacity and everyday functional outcomes in schizophrenia. J Clin Exp Neuropsychol. 2012;34:467-475.
32. Green MF, Nuechterlein KH, Kern RS, et al. Functional coprimary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry. 2008; 165: 221-228.
33. Keefe RSE, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A. Characteristics of the MATRICS consensus cognitive battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res. 2011; 125: 161-168.
34. Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ, 2009. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol. 2009; 31: 848-859.
35. Barnett JH, Robbins TW, Leeson VC, Sahakian BJ, Joyce EM, Blackwell AD. Assessing cognitive function in clinical trials of schizophrenia. Neurosci Biobehav Rev. 2010; 34: 1161-1177.
36. Leifker FR, Patterson TL, Bowie CR, et al. Psychometric Properties of Performance-based Measurements of Functional Capacity. Schizophr Res. 2010; 119: 246-252.
37. Velligan DI, Frederick M, Mitz J, et al. The reliability and validity of the MATRICS functional assessment battery. Schizophr Bull. 2014; 40: 1047-1052.
38. Bowie CR, McGurk SR, Mausbach B, Patterson TL, Harvey PD. Combined cognitive remediation and functional skills training for schizophrenia: Effects on cognition, functional competence, and real-world behavior. Am J Psychiatry. 2012; 169: 710-718.
39. Saperstein AM, Thysen J, Medalia A. The Measure of Insight into Cognition: reliability and validity of clinician-rated and self-report scales of neurocognitive insight for schizophrenia. Schizophr Res. 2012; 134: 54-58.
40. Keefe RSE, Poe M, Walker TM, Kang JW, Harvey PD. The Schizophrenia Cognition Rating Scale (SCoRS): Interviewbased assessment and its relationship to cognition, real-world functioning and functional capacity. Am J Psychiatry. 2006; 163: 426-432.
41. Ventura J, Reise SP, Keefe RS, Hurford IM, Wood RC, Bilder RM. The Cognitive Assessment Interview (CAI): Reliability and validity of a brief interview-based measure of cognition. Schizophr Bull. 2013; 39: 583-591.
42. Durand D, Strassnig M, Sabbag S, et al. Factors influencing self-assessment of cognition and functioning in schizophrenia: Implications for treatment studies. Eur Neuropsychopharmacol. 2015; 25: 185-191.
43. Sabbag S, Twamley EW, Vella L, Heaton RK, Patterson TL, Harvey PD. Assessing everyday functioning in schizophrenia: Not all informants seem equally informative. Schizophr Res. 2011; 131: 250-255.
44. Patterson TL, Semple SJ, Shaw WS, Grant I, Jeste DV. Researching the caregiver: Family members who care for older psychotic patients. Psychiatr Ann. 1996; 26: 772-784.
45. Buchanan RW, Davis M, Goff D, Green MF, Keefe RSE, Leon A, Nuechterlein K, Laughren T, Levin R, Stover E, Fenton W, Marder, S. A Summary of the FDA-NIMHMATRICS workshop on clinical trial designs for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005; 31: 5-19.
46. Bowie CR, Twamley EW, Anderson H, et al. Self-assessment of functional status in schizophrenia. J Psychiatric Res. 2007; 41: 1012-1018.
47. Bellack AS, Green MF, Cook JA, et al. Assessment of community functioning in people with schizophrenia and other severe mental illnesses: A white paper based on an NIMHsponsored workshop. Schizophr Bull. 2007; 33: 805-822.
48. Schneider LC, Struening EL. SLOF: A behavioral rating scale for assessing the mentally ill. Soc Work Res Abstr. 1983; 19: 9-21.
49. Germine L, Nakayama K, Duchaine BC, Chabris CF, Chatterjee G, Wilmer JB. Is the Web as good as the lab? Comparable performance from Web and lab in cognitive/perceptual experiments. Psychon Bull Rev. 2012; 19: 847-857.
50. Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res. 2011;127: 188-194.
51. Keefe RSE, Davis VG, Spagnola NB, et al. Reliability, validity and treatment sensitivity of the schizophrenia cognition rating scale. Eur Neuropsychopharmacol. June 28, 2014; doi: 10.1016/j.euroneuro.2014.06.009.
52. Fuchs E, Flügge G. Adult neuroplasticity: more than 40 years of research. Neural Plast. May 4, 2014. doi: 10.1155/2014/541870. Review.
53. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry. 2007; 164: 1791-1802.
54. Gupta M, Bassett E, Iftene F, Bowie CR. Functional outcomes in schizophrenia: understanding the competence-performance discrepancy. J Psychiatr Res. 2012; 46: 205-211.
55. Michalopoulou PG, Lewis SW, Wykes T, Jaeger J, Kapur S. Treating impaired cognition in schizophrenia: The case for combining cognitive-enhancing drugs with cognitive remediation. Eur Neuropsychopharmacol. 2013; 23:790-798.
56. Chou HH, Twamley E, Swerdlow NR. Towards medicationenhancement of cognitive interventions in schizophrenia. Handb Exp Pharmacol. 2012; 213: 81-111.
57. Evins AE. Cognitive remediation with D-cycloserine added to cue exposure therapy. Abstract presented at the 2012 American College of Neuropsychopharmacology meeting, Hollywood, FL, Dec. 2-6, 2012.
58. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch D, Cohen J, Essock S, Fenton WS, Frese FJ, Gold JM, Goldberg T, Heaton R, Keefe RSE, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger D, Young AS, Zalcman S, Marder SR. The MATRICS consensus cognitive battery; Part 1: Test selection, reliability, and validity. The American Journal of Psychiatry, 2008; 165(2): 203-213.
59. Bauer RM, Iverson GL, Cernich AN, Binder LM, Ruff RM, Naugle RI. Computerized neuropsychological assessment devices: joint position paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology. Clin Neuropsychol. 2012;26(2):177-96.